A 41-year-old womanand her 2 sons had Type V hyperlipoproteinemia.
Introduction
Type V hyperlipoproteinemia is characterized by marked hypertriglyceridemia due to increased serum chylomicron and very low density protein (VLDL) in the fasting state. Triglyceride (TG) rich lipoprotein probably contains both atherogenic and non-atherogenic particles (1) . The measurement of remnant-like particles (RLP) reflects chylomicron or VLDLremnants which are most likely atherogenic particles (2, 3) . Apolipoprotein E, a protein constituent of TGrich lipoprotein, has 3 major alleles (E2, E3, E4). In the present study, we investigated a case of familial TypeV hyperlipoproteinemia with hyper-RLP-cholesterol (ch) and RLP-TG, associated with apolipoprotein E phenotype.
Case Report
A 41-year-old womancame to our hospital one year previously because of hyperlipidemia found on her first health examination. Her past history showed nothing in particular (alcohol non-drinker). Her father had died of gastric cancer at the age of 70, and her mother had died of acute myocardial infarction at 59. Her physical examination showed the following: height 162 cm, weight 62 kg (body mass index: 23.6 kg/ m2), blood pressure 130/84, pulse rate 76/min. There was no abnormality in cornea, conjunctiva, fundus, neck or chest. The liver, palpable 2 cmbelow the right costal margin, was smooth and of normal consistency. There was no lymphadenopathy.
There was no xanthoma in skin or tendons. There was no abnormality in urinalysis, hematology, liver function, renal function or electrolytes, nor was any abnormality detected in the chest X-ray film or electrocardiogram. An abdominal echogram showed brightness, indicating a fatty liver; 75g of glucose ingestion showed a normal pattern. Total cholesterol (T-ch) value was 209 mg/dl, high density lipoprotein (HDL)-ch value was 26 mg/dl, TG value was 1,280 mg/dl and chylomicron was positive.
Materials and Methods
RLP-ch and TG assay method (2, 3) Five mg each of anti-apolipoprotein B-100 (JI-H) and anti apolipoprotein A-I (H-12) IgG were coupled to 1 ml of CNBr-Remnant-Like Particle and Apolipoprotein E4 the recommendationsof the manufacturer. The remaining active sites on the gels were blocked with 0.2 Mglycine. Before use, the gels were conditioned to reduce non-specific binding by two cycles of incubation with fetal calf serum for 1 hour at room temperature with gentle shaking, followed by washing with 0. 1 Macetic acid in 0.5 MNaCl. Five jlxI of serum was added to 300 jil of immunoaffinity mixed gel suspension which contained 25 |Ltl of apolipoprotein B-100 gel (125 |ig of IgG) and 25 |il apolipoprotein A-I gel (125 |ig of IgG). The reaction mixture was gently shaken for 60 minutes at room temperature to assure complete mixing. The test tubes were allowed to sit for 10 minutes and 30 |Lil (or an adequate amount) of the supernatant was taken to assay cholesterol with the Mercko test diagnostic kit (Kanto-kagaku, Tokyo, Japan). The normal range of serum RLP-ch was under 5 mg/dl and serum RLP-TGwas under 50 mg/dl.
Analysis of lipid and protein TG and T-ch were measured by enzymatic determination. HDL-chwas measured by precipitation and enzymatic determination. Chylomicron, low density lipoprotein (LDL) and
VLDLwere measured by the heparin/Ca precipitation method. Theelectrophoretic mobility of the serumwasdetermined using 1 %agarose gel. Apolipo-protein AI, All, B-100, CII, CIII and E were measured by turbidimetric immunoassay (4).
Apolipoprotein E phenotyping Apolipoprotein E phenotype was determined using isometric electrophoresis (Phenotyping Apo E IEF System, Jyoukou Co. Ltd., Tokyo, Japan). Postheparin plasma lipolitic activities Lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) were released into the circulation by intravenous heparin injection at a dose of 60 U/kg body weight. After 15 minutes, blood was drawn into tubes containing 4 mMEDTA. The plasma was immediately separated at 4°C by centrifugation at 2,700 rpm for 12 minutes and promptly frozen at -20°C. The assay was done by the method of Krauss, et al (5).
Results
As shown in Table 1 , the TGvalue was markedly elevated and chylomicron was positive, however, T-ch and LDLvalues were within the normal range. VLDLand apolipoprotein B-100, CII, CIII and E were increased. As shown in Fig. la , the electrophoretic mobility of serum lipoprotein showed a chylomicron fraction, but no broad (3 pattern. RLP-ch and RLP-TG values were increased and the activity of LPLwas increased. Apolipoprotein E phenotype was E3/E4 (Table 1) . Since TG, RLP-ch and RLP-TGlevels remained constant during 2 months of diet therapy, we administered her 400 mgof daily of bezafibrate (Kissei Co. Ltd., Nagano, Japan). After bezafibrate administration, T-ch levels remained nearly unchanged. HDL-ch increased slightly and TGlevels ranged from 150 to 240 mg/dl. VLDL, apolipoprotein B-100 and E were decreased. RLP-ch ranged from 2.9 to 7.9 mg/dl and RLP-TG ranged from 30 to 50 mg/dl ( Table 2 ). The chylomicron fraction began to disappear 4 months after start of bezafibrate administration (Fig. lb) . The laboratory data of her 2 sons are shown in Table 3 . Both sons had hypertriglyceridemia with increased chylomicron, VLDLand RLP-TG, and neither had hypercholesterolemia. The younger son (age 9) had increased RLP-ch levels although the elder son (age 12) had normal RLP-ch levels. The apolipoprotein E phenotype of the elder son was E3/E3 and the phenotype of the younger son was E3/E4. In the present patient, after the administration of bezafibrate, the TG, RLP-ch and RLP-TGlevels decreased markedly (% change: TG: 80%, RLP-ch: 92%, RLP-TG: 94%) and the chylomicron fraction disappeared. The major action of this drug is to lower serum TG(9). It also decreases the mean TG levels by about 50% in Type V as well as IV hyperlipoproteinemic patients (10). Weused the drug because high TG levels indicated the use of this drug. Moreover, familial hypercholesterolemic patients with apolipoprotein E4 show a greater reduction in serum TGlevels as well as T-ch levels with probucol treatment than those without apolipoprotein E4 ( 1 1 ).
The present case maybe a special case because only one family was reported. Morestudies will be necessary to determine if hypertriglyceridemic patients with or without apolipoprotein E4 show a greater reduction in serum TG, RLP-ch and RLP-TG levels with lipid-lowering agents such as bezafibrate.
